Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
(Posted: 11/29/2012) - Long-term results from two clinical trials confirm that certain patients with rare brain tumors called anaplastic oligodendrogliomas live substantially longer if they are treated with a combination of chemotherapy and radiation therapy rather than radiation alone.
For Some Breast Cancers, New Drug May Be Treatment Option
(Posted: 06/13/2012, Updated: 11/29/2012) - Results from an international clinical trial suggest that women with metastatic, HER2-positive breast cancer that is no longer responding to the targeted therapy trastuzumab (Herceptin) may soon have a new treatment option. Women who received the investigational drug trastuzumab emtansine (T-DM1) lived more than 3 months longer without their tumors progressing than women who received the chemotherapy drug capecitabine (Xeloda) and the targeted drug lapatinib (Tykerb).
Exercise, Behavioral Therapy Reduce Menopausal Symptoms Caused by Breast Cancer Treatment
(Posted: 10/25/2012) - Women with breast cancer who were suffering from treatment-related menopausal symptoms experienced symptom relief with cognitive behavioral therapy, physical exercise, or both, according to a Dutch study published October 8, 2012, in the Journal of Clinical Oncology.
Observation as Good as Surgery for Some Men with Prostate Cancer
(Posted: 09/07/2012) - Many men diagnosed with early-stage prostate cancer could forego radical prostatectomy and live as long as men who have immediate surgery, according to long-awaited results from a clinical trial published July 19, 2012, in the New England Journal of Medicine (NEJM).
For Some Skin Cancers, Targeted Drug Hits the Mark
(Posted: 06/15/2012) - Two studies reported June 7, 2012, in the New England Journal of Medicine indicate that the drug vismodegib (Erivedge™) can elicit responses in people with advanced or metastatic basal cell carcinoma and help shrink or prevent tumors in those with basal cell nevus syndrome.